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Case Reports & Case Series

Cerebellar infarction requiring surgical decompression in patient with
COVID 19 pathological analysis and brief review
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Background: This report and literature review describes a case of a COVID-19 patient who suﬀered a cerebellar
stroke requiring neurosurgical decompression. This is the ﬁrst reported case of a sub-occipital craniectomy with
brain biopsy in a COVID-19 patient showing leptomeningeal venous intimal inﬂammation.
Clinical description: The patient is a 48-year-old SARS-COV-2 positive male with multiple comorbidities, who
presented with fevers and respiratory symptoms, and imaging consistent with multifocal pneumonia. On day 5 of
admission, the patient had sudden change in mental status, increased C-Reactive Protein, ferritin and elevated
Interleukin-6 levels. Head CT showed cerebral infarction from vertebral artery occlusion. Given subsequent rapid
neurologic decline from cerebellar swelling and mass eﬀect on his brainstem emergent neurosurgical intervention was performed. Brain biopsy found a vein with small organizing thrombus adjacent to focally proliferative intima with focal intimal neutrophils.
Conclusion: A young man with COVID-19 and suspected immune dysregulation, complicated by a large cerebrovascular ischemic stroke secondary to vertebral artery thrombosis requiring emergent neurosurgical intervention for decompression with improved neurological outcomes. Brain biopsy was suggestive of inﬂammation
from thrombosed vessel, and neutrophilic inﬁltration of cerebellar tissue.

1. Introduction

2. Case presentation

The ﬁrst reported case of COVID-19 was reported to the WHO in
December 2019 [1]. Large vessel stroke has been shown to be a presenting sign or complication of SARS-Cov-2 infection [2]. Oxley et al
reported ﬁve large vessel stroke in patients, with four requiring neuroendovascular intervention, including one patient that also required
neurosurgical intervention (hemicraniectomy) [2]. We report the ﬁrst
case of COVID-19 vertebral artery thrombosis related cerebellar circulation stroke requiring suboccipital decompressive craniectomy.

This is a 48-year-old African American male with diabetes, hypertension, untreated latent tuberculosis, who presented with one week
history of fevers, cough, shortness of breath, and hypoxia. The patient
had a prior history of tuberculosis for which he had not been treated for
and had not shown active disease on prior chest x-rays. Initial and
hospital clinical characteristics are shown in Supplementary Table 1.
The patient tested positive for COVID-19 on presentation with detection
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
ribonucleic acid from a nasophargyngeal swab specimen using the
Cepheid Xpert Xpress SARS-CoV-2 rapid 30 min Real-time Polymerase

Abbreviations: ARDS, acute respiratory distress syndrome; BiPaP, Bilevel positive airway pressure; COVID 19, Corona Virus Disease 2019; CP, cerebellopontine;
CRP, C-reactive protein; CT, computed tomography; CTA, CT angiography; CXR, chest X-ray; FiO2, fraction of inspired oxygen; SARS-COV-2, severe acute respiratory
syndrome coronavirus 2; STAT, statum which is Latin meaning immediately; t-PA, tissue plasminogen activator; WHO, World Health Organization
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daily for 5 doses for moderate ARDS. His interleukin-6 levels were also
checked and these were elevated at 555 pg/ml. The remainder of the
patient’s stroke work up did not identify any abnormal cardiac rhythm,
cardiac embolus, dissection, or atherosclerotic disease process.
Over the next 48 h, on day 6, and day 7 of admission, his mental
status declined further and he was intubated. A repeat CT of the head
showed increasing mass-eﬀect on the fourth ventricle in the right cerebellar hemisphere, with eﬀacement of the CP angle cisterns and
midline shift (Fig. 2C, D).
On hospital day 9 patient had Cushing response (hypertension with
bradycardia) indicating an increase in the intracranial pressure with
STAT consultation of neurosurgery by the primary team. The systolic
blood pressure increased to 182 mmHg and heart rate decreased to 52
beats per minute. STAT CT head showed left cerebellar stroke with mass
eﬀect on the fourth ventricle and obliteration of the paramesencephalic
cistern. No gross hydrocephalus (Fig. 2E). Due to the patient rapid
clinical decline, Cushing response, and radiographic ﬁndings of mass
eﬀect on the brainstem it was decided the patient would need emergent
cerebellar decompression and placement of an external ventricular
drainage catheter in order to alleviate intracranial hypertension. The
neurologic decline was attributed to increased cerebellar edema secondary from the original stroke event. The Patient was given weight
dosed Protamine 7.5 mg to reverse the heparin gtt and mannitol in
anticipation for emergent suboccipital craniectomy and placement of
right external ventricular drain for intracranial pressure (ICP) monitoring and drainage. The surgery was performed under COVID-19
precautions in a negative pressure operating room and all staﬀ wore
Powered Air Purifying Respirator (PAPR) throughout the case and with
all clinical interactions with the patient.
The surgery was performed by the primary author with the patient
supine initially for placement of right external ventricular drainage
catheter (EVD) using standard landmarks at the right Kocher’s point.
Following EVD placement the patient was positioned prone and underwent a 4 cm × 3 cm suboccipital decompressive craniectomy with
opening of the foramen magnum. A left cerebellar biopsy was obtained
from infarcted tissue including an arterial and venous vessel and
1 cm × 1 cm section of parenchyma and dura.
Pathology revealed a single vessel, presumably a vein, with a small
organizing thrombus adjacent to a focally proliferative intima with
intimal neutrophils, without evidence of arterial vasculitis. Focal scattered neutrophils within the molecular layer of the cerebellar tissue
were also noted. (Fig. 3).
On post operative day (POD) 1 patient had ICP’s in the high 30 s
that were controlled with mannitol, hypertonic saline and EVD drainage. Mannitol was started by the neurocritical care service and was
discontinued by the neurosurgical service as there is no evidence of its
beneﬁt in a patient with external ventricular drainage. The EVD was
weaned and discontinued on POD 6. Patient began to follow commands
on the right side and remained hemi paretic on the left side. Patient
respiratory status was improved and transferred to a rehabilitation facility and neurologically stable in follow up.

Fig. 1. Chest X-Ray on admission: Multifocal pulmonary consolidative opacities
are present.

Chain Reaction (RT-PCR) assay®. Patient initial chest x-ray shown in
Fig. 1.
Patient fevers had continued with a T-max of 102.0 degrees
Fahrenheit. His oxygen requirement had remained stable at 2 L of nasal
cannula. His work of breathing was minimal and he appeared comfortable. On review of his labs, the white count remained elevated to
11.1 per cubic millimeter, creatinine remained at 0.9 mg per deciliter,
with normal liver enzymes, ferritin was at 583 ng per milliliter with a
CRP of 33 mg per deciliter. Given stable oxygen requirements he was
conservatively managed. The patient was started on subcutaneous heparin injection 5000 mg three times a day for deep venous thrombosis
prophylaxis. Over the next 2 days the patient continued to require
supplemental oxygen, and his oxygen requirement worsened to 6 L via
nasal cannula, with slightly increased work of breathing on hospital day
4.
He was stable until day 5 of admission, when his oxygen requirements started to worsen. On day 5 his oxygen requirements acutely
declined, and he was placed on high ﬂow nasal cannula and later
transitioned to BiPAP with an FiO2 of 60%. He was noted to be tachypneic, and along with these changes his mental status had acutely
declined with noted right gaze deviation, and aphasia. He spiked a fever
of 101°F degrees Fahrenheit, and review of labs showed an increase in
white count to 16.6 per cubic millimeter, along with increasing platelets to 453 per cubic millimeter. His CRP had increased from 27.8 mg
per deciliter to 48.4 mg per deciliter, along with his ferritin from 723 ng
per milliliter to 955 ng per milliliter. His lactate had also increased to
2.4 millimoles per liter. A CT Angiogram of the head was performed
which showed thrombotic occlusion of the cervical and intracranial
segments of the left vertebral artery along with thrombosis of the
proximal cervical segment of the right vertebral artery and extension of
the thrombus from the thrombosed left vertebral artery into the proximal basilar artery. Due to evidence of clot extension into the basilar
artery and stroke symptoms it was determined that the patient had a
thrombosis and not a hypoplastic vertebral artery (Fig. 2A, B). His chest
x-ray remained stable. He received IV TPA and was placed on low dose
heparin by the neurology team. The patient had no neurologic improvement following the administration of TPA and being placed on a
heparin drip. Stroke work up revealed anti-cardiolipin IgM and Beta 2
GPI IgA antibodies, which was concerning for anti-phospholipid antibody syndrome. One dose of oﬀ-label 8 mg/kg Tocilizumab was administered via emergency use protocol, upon admission to the ICU for
suspected immune dysregulation/cytokine release storm syndrome due
to COVID-19. The patient was also started on dexamethasone 10 mg

3. Discussion
Much of the pathophysiology pertaining to SARS-Cov-2 infection is
not well understood. There has been some resemblance to disease
caused by SARS-COv-2 to SARS-COV and MERS; with direct infection of
type-II pneumocytes, via the ACE-2 receptor binding domain during the
initial phase of illness [3–5]. The pathogenesis also involves immune
dysregulation, which has been noted in severely ill patients with SARSCov-2 infection [6–8]. Two distinct syndromes have been noted in patients with COVID-19; immune dysregulation and macrophage activation syndrome [8]. An increase in inﬂammatory cytokines, has been
noted in both, with majority of patients noted to have elevated interleukin-6 levels [8]. Levels of Interleukin-6 have also been shown to
correlate with increased severity of disease, disease progression and
2
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Fig. 2. Noncontrast Head CT Time Course. A. Hospital Day 5. Noncontrast head CT at time of stroke alert, note no hypodensity, no hydrocephalus and no mass eﬀect
on fourth ventricle. B. CT Angiogram head at time of stroke alert, note vertebral artery occlusion (arrows). C. Hospital Day 6. CT head non-contrast shows left
cerebellar infarct with eﬀacement of the CP angle cistern and left-to-right midline shift without hydrocephalus, fourth ventricle remains patent. D. Hospital Day 7. CT
head non-contrast shows evolving left cerebellar stroke with increasing mass eﬀect on the fourth ventricle without hydrocephalus. E. Hospital Day 9. CT head noncontrast shows left cerebellar infarct with signiﬁcant mass eﬀect on the fourth ventricle and paramesencephalic cistern. No hydrocephalus.

Chinese [15]. Given interleukin-6 levels have also been shown to be
elevated in patients critically ill with COVID-19, it would be interesting
to know if there is a correlation between risk of stroke and coagulopathy with increased levels of interleukin-6 [8]. It could be hypothesized that immune dysregulation can predispose patients to anti-phospholipid antibody syndrome or development of clinically signiﬁcant
coagulopathy, and hence, increase their risk of stroke. However, whether this eﬀect holds true in the presence of co-morbidities could be
better assessed in larger clinical trials.
Our patient was identiﬁed to be in a state of immune dysregulation,
given increased CRP, ferritin, and interleukin-6 levels, and hence one
dose of oﬀ-label Tocilizumab was given in an attempt rescue immune
dysregulation by SARS-CoV-2. Tocilizumab is an Intereukin-6 receptor
antagonist, shown to be beneﬁcial in treatment of patients with severe
disease from SARS-Cov-2 in smaller studies, however, larger studies are
needed and are underway to examine the impact on morbidity and
mortality [16,17]. Tocilizumab did not demonstrate increased risk of
hypercoagulability, thrombosis or drug interaction that led to increased
coagulability [18]. Some beneﬁt was noted in our patient, with improving markers of inﬂammation, and respiratory status, however, the
clinical picture was complicated by severity of stroke and associated
edema with impending herniation.
The patient had been on supportive care prior to his stroke and was
not given any medication that had side eﬀects or drug interactions that
would increase his risk of thrombosis and stroke.
Currently, treatment modalities for SARS-Cov-2 infection are limited, with need for larger studies, and randomized trials showing a
beneﬁt in outcomes and mortality. Recently, the FDA approved use of
convalescent plasma for critically ill patients with COVID-19, and more
recently, emergency use authorization of use of Remdesivir to allow for
distribution in the United States for treatment of severe disease. At the
time of this writing, Remdesivir is only available to a few sites in United
States, with majority with access for compassionate use in pregnant
women and children [19].
Convalescent plasma has been studied in infections with SARS-CoV
and MERS, and it is hypothesized it may improve mortality in patients
infected with SARS-Cov-2, with good experience noted in smaller studies [20–22]. Several clinical trials are ongoing to examine the eﬀect of
convalescent plasma, including one at our institution. It would be interesting to know if early administration of convalescent plasma is
beneﬁcial is prevention of cytokine cascade, increased levels of immunoregulatory cytokines, and immune dysregulation. This might reduce the impending severity of disease, and possibly mortality from
infection.
Arterial thrombosis and associated intracerebral stroke frequency
has been noted as the current COVID-19 pandemic continues
[2,25,26,28]. Previous descriptions of stroke phenomenon requiring
either neuro endovascular intervention or formal surgical intervention
have been reported, acute ischemic events involving peripheral arterial

Fig. 3. H&E permanent section of left cerebellum brain biopsy, note histology
leptomeningeal vein with neutrophilic inﬁltrates (arrows) in the blood vessel
wall. The asterisk denotes a ﬁbrin plug in the lumen of the vein. The scale bar
equals 50 µm.

poor prognosis in addition to certain other biomarkers; these include
elevated ferritin, elevated white blood cell count, lymphopenia, and
elevated platelet count [9,10].
Apart from biomarkers of inﬂammation, co-morbities including
diabetes and hypertension, have also been shown to be risk factors for
severe disease [11,12]. This was also noted in our patient, who was a
diabetic and had hypertension increasing his risk for progression to
severe disease. He was noted to have lymphopenia, elevated CRP, ferritin, and was later shown to have increased interleukin-6 levels,
showing immune dysregulation. Moreover, our patient also tested positive for anti-cardiolipin IgM and Beta 2 GPI IgA antibodies, which is
concerning for anti-phospholipid antibody syndrome; which has also
been described in two other diabetic patients with stroke one of which
also had signiﬁcant coagulopathy similar to our patient who developed
sudden increase in D-dimer (> 20.0 ng per milliliter) and elevated PT,
PTT and low ﬁbrinogen levels (158 mg per deciliter), interestingly with
a normal platelet count on day 6 of admission [13]. Infection accounts
for the cause of 8–11% of cases of cerebral venous thrombosis [14]. Our
patient had radiographic evidence of arterial thrombosis and pathological evidence of venous thrombosis. Larger studies will be helpful to
examine the impact of diabetes in COVID-19 patients as a risk factor for
development of anti-phospholipid antibodies, coagulopathy and stroke.
Interestingly, severity of COVID-19 has been shown to correlate
with risk of coagulopathy and stroke in Caucasian patients, and in
general, ethnicity has been shown have a major eﬀect in the risk of
thrombosis with African Americans at higher risk than Caucasians or
3
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vessels with limb ischemia have also been noted [2,22]. Hypotheses as
to the pathophysiologic causes have been discussed and a virus related
state of hypercoagulability may be the direct result in select groups of
individuals [2,23]. Unfortunately the systemic cause of hypercoagulability has not been pinpointed and trends associated with d-dimer
elevations during the course of arterial vessel thrombosis both in our
case and others have been described [24]. Whether or not the viral
infection results in a vasculitic response to particular organs is unclear,
and at this time early markers of inﬂammation may need to be followed
closely in order to proactively anti-coagulate patients who may be
deemed at risk of thrombus development [27,28].
The case presented from our institution, demonstrates a trend in ddimer elevation and possible concurrent vessel thrombosis. The brain
biopsy demonstrated cerebral venous neutrophilic inﬁltration of the
intimal layer with adjacent ﬁbrin clot formation. The artery did not
show any signs of vasculitis, but that may have been secondary to
sampling error. As no embolic source was uncovered during the investigations, and drug related thrombosis was ruled out, it was hypothesized our patient stroke was secondary to large vessel vasculitis
and venous phlebitis as evidenced by radiologic imaging and brain
biopsy. The patient was not treated with corticosteroids prior to his
stroke. The patient receive dexamethasone as treatment for ARDS after
being admitted to the ICU. There are currently ten clinical trials underway worldwide as per clinicaltrials.gov that are looking at the eﬃcacy of dexamethasone in COVID-19 patients. Corticosteroids as a
treatment for cerebral vasculitis is well documented [29]. It would be
interesting to see if these trials show lower incidence of strokes in their
cohorts. COVID-19 complicated with cerebral and large vessel vasculitis
and its treatment will require a need for randomized clinical trials
showing beneﬁt in outcomes and mortality.
The infectious process of COVID-19 remains a systemic event with
pathophysiologic evidence of vasculitis involving the lungs, venous and
arterial systems. As the disease process is further deﬁned, it will be
imperative that new diagnostic strategies are developed along with
tracking of individual coagulopathy. Early neurosurgical consultations
may have to be considered when patients present with neurologic
changes or suspected intracranial ischemic phenomenon. As case
numbers and data are compiled, trends may be noted thus simplifying
treatment modalities necessary for thrombo-embolic complications.
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4. Conclusion
This is a report of a patient with COVID-19 immune dysregulation
who developed an acute cerebellar ischemic stroke secondary to vertebral artery thrombosis. A biopsy showed venous phlebitis with neutrophilic inﬁltration of the vessel wall. The patient had a large vessel
occlusion from presumed arteritis with intracranial evidence of venous
involvement indicating a possible pathophysiologic mechanism for incidence of thrombosis and stroke in COVID-19 patients.
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